Nephrectomy Followed by Interferon Alfa-2b Compared with Interferon Alfa-2b Alone for Metastatic Renal-Cell Cancer
New England Journal of MedicinePublished 6 December 2001
Robert C. Flanigan, Sydney E. Salmon, Brent A. Blumenstein, Scott I. Bearman, Vivek Roy, Patrick C. McGrath
Citations1,722
SJR quartileQ1
SJR score19.08
SNIP13.47
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Nephrectomy followed by interferon therapy results in longer survival among patients with metastatic renal-cell cancer than does interferons therapy alone.
Abstract
Nephrectomy followed by interferon therapy results in longer survival among patients with metastatic renal-cell cancer than does interferon therapy alone.
Keywords
MedicineBiochemistry, Genetics and Molecular Biology
Analysis of Survival Data
5,999 Citations2018D. R. Cox, David Oakes
BiometricsSequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial
2,302 Citations1975Stuart Pocock, Richard Simon
A new general procedure for treatment assignment is described which concentrates on minimizing imbalance in the distributions of treatment numbers within the levels of each individual prognostic factor.
Investigational New DrugsSouthwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria
616 Citations1992Stephanie Green, Geoffrey R. Weiss
The Southwest Oncology Group has extended the toxicity criteria, incorporating additional new criteria for biological agents, radiation therapy, surgery, and hormonal agents.
Annals of Internal MedicineMetastatic Renal Cancer Treated with Interleukin-2 and Lymphokine-Activated Killer Cells
355 Citations1988Richard I. Fisher, CHARLES A. COLTMAN +12 more
The Journal of UrologySurgery for Metastatic Renal Cell Carcinoma
334 Citations1967Richard G. Middleton
Journal of Clinical OncologyMulticenter, Randomized, Phase III Trial of CD8<sup>+</sup> Tumor-Infiltrating Lymphocytes in Combination With Recombinant Interleukin-2 in Metastatic Renal Cell Carcinoma
213 Citations1999Robert A. Figlin, John A. Thompson +6 more
Treatment with CD8(+) TILs did not improve response rate or survival in patients treated with low-dose rIL-2 after nephrectomy, and the study was terminated early for lack of efficacy.
Urologic Clinics of North AmericaCYTOTOXIC CHEMOTHERAPY FOR ADVANCED RENAL CELL CARCINOMA
206 Citations1993Alan Yagoda, Daniel P. Petrylak +1 more
Although some data suggest that a few drugs need further evaluation, at this time, renal cell carcinoma must be considered a chemotherapeutically resistant cancer.
Journal of Clinical OncologyRecombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration.
166 Citations1987Hyman B. Muss, J J Costanzi +8 more
This trial demonstrates modest, but definite antitumor activity for recombinant interferon in advanced renal cell carcinoma, and administration with lower dose and toxicity is as effective as treatment administered IV.
The Journal of UrologyPrognostic Factors for Survival in Patients with Metastatic Renal Cancer Treated with Biological Response Modifiers
142 Citations1995Sridhar Mani, Mary B. Todd +2 more
Risk factors of ECOG performance status, sarcomatoid histology, bone metastasis, history of nephrectomy, recent weight loss and recurrence at the renal bed are predictive of survival in patients treated with biological response modifiers.
CancerInterferon treatment of renal cell carcinoma. Current status and future prospects
137 Citations1987Susan E. Krown
Review of the data suggests that maximal response rates are achieved when interferon alpha is administered within a fairly restricted range of moderate to high doses, whereas extremely low or extremely high dosage regimens appear less likely to induce therapeutic response.
The Journal of UrologyIs Nephrectomy Justified in Patients with Metastatic Renal Carcinoma?
136 Citations1975Douglas E. Johnson, Kelly E. Kaesler +1 more
Analysis of the cumulative survival rates revealed that nephrectomy significantly increased survival only for those patients pesenting exclusively with osseous metastases, and did not alter survival for patients with pulmonary and/or soft tissue metastases.
The Journal of UrologyTreatment of Advanced Renal Cell Carcinoma—Traditional Methods and Innovative Approaches
129 Citations1983Jean B. deKernion
The Journal of UrologyCYTOREDUCTIVE SURGERY BEFORE HIGH DOSE INTERLEUKIN-2 BASED THERAPY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
112 Citations1997McClellan M. Walther, James Chih‐Hsin Yang +3 more
Although the impact of cytoreductive surgery on response to immunotherapy remains undefined, this combination of primary debulking and systemic IL-2 can result in durable complete tumor regression in some patients with metastatic renal cell carcinoma.
The Journal of UrologyPreparative Cytoreductive Surgery in Patients with Metastatic Renal Cell Carcinoma Treated with Adoptive Immunotherapy with Interleukin-2 or Interleukin-2 Plus Lymphokine Activated Killer Cells
93 Citations1990Cary N. Robertson, W. Marston Linehan +6 more
Further studies, including a prospective, randomized trial, will be required to define the role of nephrectomy in patients with advanced renal cell carcinoma before treatment with interleukin-2 based immunotherapies.
CancerRegression of metastatic renal cell carcinoma following nephrectomy
76 Citations1972David Garfield, B. J. Kennedy
It appears that older males with only pulmonary metastases make up the majority of patients in whom regression of metastases after nephrectomy has been observed, and Hormonal and immunologic factors are implicated in this phenomenon.
CancerActive specific immunotherapy of stage iv renal carcinoma with aggregated tumor antigen adjuvant
69 Citations1980James A. Neidhart, Samuel G. Murphy +2 more
The overall survival rate for the 30 patients entered is equivalent to reported survival rates for patients with extensive disease treated with aggressive surgery with or without chemotherapy, and it is believed these results offer strong preliminary evidence of efficacy of this particular type of therapy in an advanced human malignancy.
PubMedCytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience.
61 Citations1996J R Franklin, Robert A. Figlin +3 more
The results support the argument for an aggressive approach (surgery combined with IL-2-based immunotherapy including TILs) in the management of metastatic RCC.
The Journal of UrologyRenal Cell Carcinoma Metastatic to the Lung: Potential Benefit in the Combination of Biological Therapy and Surgery
52 Citations1996Simon Tanguay, David A. Swanson +1 more
The results suggest a role for an aggressive surgical approach in select patients with metastatic renal cell carcinoma, and demonstrate that patients who do not achieve a complete response to biological therapy may benefit from surgical resection of residual disease.
CancerExpression of the multidrug transporter, P-glycoprotein, in renal and transitional cell carcinomas
45 Citations1993Kenryu Nishiyama, T Shirahama +6 more
Examination of the expression level of P‐glycoprotein in RCC and transitional cell carcinomas found it to be overproduced in multidrug‐resistant cells and thought to function as an energy‐dependent drug efflux pump.
The Journal of UrologySERUM IMMUNOSUPPRESSIVE ACIDIC PROTEIN AND NATURAL KILLER CELL ACTIVITY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA BEFORE AND AFTER NEPHRECTOMY
35 Citations2000Keita Fujikawa, Yoshiyuki Matsui +5 more
The study implies that nephrectomy may be beneficial in patients with elevated serum C-reactive protein before treatment, and those in whom nadir C- reactive protein decreases postoperatively to within the normal range may expect longer survival when surgery is combined with postoperative immunotherapy.
The Journal of UrologyRenal Cell Carcinoma: The Ochsner Medical Institution Experience (1945–1978)
33 Citations1983Harold A. Fuselier, S. Lee Guice +5 more
The stage and differentiation of the tumor were more important to outcome than choice of therapy and the type of nephrectomy did not affect survival and lymphadenectomy was only of value in staging the disease.
The Journal of UrologyFailurel of Immunotherapy for Metastatic Renal Cell Carcinoma
32 Citations1986Jackson E. Fowler
It is concluded that these treatment regimens have minimal activity against metastatic renal cell carcinoma.
PubMedRole of surgery in patients with metastatic renal cell carcinoma.
27 Citations1996Flanigan Rc
The role of surgery in metastatic renal cancer continues to evolve and the clinical usefulness of nephrectomy in patients with unresectable metastases remains to be proved.
Urologic Clinics of North AmericaThe Failure of Infarction and/or Nephrectomy in Stage IV Renal Cell Cancer to Influence Survival or Metastatic Regression
26 Citations1987Robert C. Flanigan
It is reasonable to recommend adjunctive nephrectomy only in certain selected instances, which include the control of a patient's current symptoms related to the primary disease, for example, flank pain, hematuria, fever and toxicity, anemia, erythrocytosis, and hypercalcemia.